Aminoglycosides in gynecologic infections

Area of Science:

• Gynecologic infections
• Antimicrobial therapy
• Pharmacokinetics

Background:

• Aminoglycosides are vital for treating gynecologic infections due to their efficacy against gram-negative aerobes.
• Pelvic infections often involve multiple bacterial types, necessitating broader-spectrum antimicrobial coverage.
• Shifting treatment paradigms include clindamycin or metronidazole for anaerobic coverage and aminoglycosides for aerobic gram-negative organisms.

Purpose of the Study:

• To review the role of aminoglycosides in gynecologic infections.
• To highlight the importance of amikacin as a "gold standard" agent.
• To emphasize the need for therapeutic drug monitoring in specific patient populations.

Main Methods:

• Literature review of aminoglycoside use in gynecologic infections.
• Analysis of bacterial resistance patterns and therapeutic efficacy.
• Discussion of pharmacokinetic considerations in dosing.

Main Results:

• Aminoglycosides remain essential for gram-negative aerobic coverage in gynecologic infections.
• Amikacin shows low resistance and is a benchmark for new antibiotics.
• A significant percentage of young, healthy patients may be underdosed with standard aminoglycoside regimens, requiring level monitoring.

Conclusions:

• Aminoglycosides are indispensable in treating severe and nosocomial gynecologic infections, particularly in immunocompromised or oncology patients.
• Amikacin is a preferred aminoglycoside due to its resistance profile.
• Therapeutic drug monitoring of aminoglycoside peak and trough levels is critical to ensure efficacy and prevent toxicity in gynecologic patients.